Skip to Content

Join the 'Ibrance' group to help and get support from people like you.

Ibrance News

Doctors' Group Offers Ideas for Easing Cancer Costs

Posted 19 Jul 2017 by Drugs.com

WEDNESDAY, July 19, 2017 – New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society of Clinical Oncology (ASCO) has some suggestions for easing patients' money woes. The proposals include allowing Medicare to negotiate drug prices, legalizing the importation of drugs, and adopting bundled, or group, payment programs. In ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Ibrance (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer

Posted 3 Apr 2017 by Drugs.com

March 31, 2017 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, Ibrance (palbociclib), based on the results from the confirmatory Phase 3 trial PALOMA-2. The FDA action converts the accelerated approval of Ibrance to regular ...

New Drug May Brighten Outlook for Advanced Breast Cancer

Posted 16 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 16, 2016 – A recently approved drug can help slow the progression of advanced breast cancer, a new clinical trial confirms. The drug, called palbociclib (Ibrance), was approved in the United States last year for treating advanced cases of ER-positive breast cancer. That means the cancer uses the hormone estrogen to help fuel its growth. The approval was based on an earlier-stage ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR+, HER2- Metastatic Breast Cancer

Posted 23 Feb 2016 by Drugs.com

Friday, February 19, 2016 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of Ibrance (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now Ibrance also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced o ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

New Drug Ibrance Keeps Common Breast Cancer Under Control Longer: Study

Posted 30 May 2015 by Drugs.com

SATURDAY, May 30, 2015 – Adding a new drug called Ibrance (palbociclib) to standard hormone therapy helped keep a common type of breast cancer under control measurably longer than the hormone therapy alone, a new study shows. "Palbociclib stops cancer cells from growing," said study author Dr. Nicholas Turner, team leader at the Institute of Cancer Research in London, England. Adding the drug ...

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer, Metastatic, Breast Cancer

Ibrance Patient Information at Drugs.com